News & Events

Vertex Expands into New Disease Areas and Enhances Gene Editing Capabilities Through Expanded Collaboration with CRISPR Therapeutics and Acquisition of Exonics Therapeutics

Vertex and Exonics Therapeutics have entered into a definitive agreement under which Vertex will acquire Exonics. Acquisition is anticipated to close in third quarter 2019. Combination of Exonics’ research and gene editing capabilities with Vertex’s rare disease development and commercialization expertise will advance efforts to potentially develop transformative gene editing therapies for Duchenne, Myotonic Dystrophy Type 1 and other severe neuromuscular diseases.

Read more


Media Contact

Heather Anderson
6 Degrees